Table 3– Lung function, bronchial hyperresponsiveness and allergic sensitisation at 10 and 16 years of age

	10 years of age			16 years of age
	Never asthma/rBO	rBO-remission	rBO-asthma	Never asthma/rBO	rBO-remission	rBO-asthma
Subjects n	322	95	48	322	95	48
FEV₁ % pred	98.4 (97.4–99.4)	97.1 (95.2–99.1)*	94.8 (92.2–97.4)*	101.1 (99.8–102.3)	98.1 (96.7–100.5)*	95.8 (92.5–99.1)**
FEV₁/FVC	0.88 (0.87–0.88)	0.85 (0.84–0.86)***	0.84 (0.82–0.86)***	0.88 (0.87–0.88)	0.83 (0.81–0.85)***	0.81 (0.78–0.84)***
FEF_25–75% % pred	97.7 (95.5–99.9)	87.9 (83.9–91.9)***	80.7 (75.3–86.31)***	100.2 (98.2–102.3)	89.0 (85.1–93.0)***	85.1 (78.6–91.5)***
PD₂₀ ≤8 μmol	24.2	37.9*	54.2***	10.2	20.7**	24.4**
Allergic sensitisation	26.4	36.8	41.7*	50.2	55.8	52.1

Data are presented as mean (95% CI) or % unless otherwise stated. The reference is never recurrent bronchial obstruction (rBO)/asthma. FEV₁: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; FEF_25–75%: forced expiratory flow at 25–75% of the FVC; PD₂₀: provocative dose of methacholine causing a 20% fall in FEV₁. *: p<0.05; **: p<0.01; ***: p<0.001.